Real-World data shows promise for breast cancer combo therapy
NCT ID NCT06075758
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at the safety and effectiveness of a drug called ribociclib combined with hormone therapy for people with a certain type of advanced breast cancer (HR+/HER2-). Researchers collected real-world data from 175 patients in the Middle East to track side effects and how long the cancer stayed under control. The goal was to see how well this treatment works outside of a clinical trial setting.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Amman, 11941, Jordan
-
Novartis Investigative Site
Muscat, 111, Oman
-
Novartis Investigative Site
Al Ain Abu Dhabi, United Arab Emirates, United Arab Emirates
-
Novartis Investigative Site
Dubai, United Arab Emirates, 7272, United Arab Emirates
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Chest-Injected drug drain Cancer's fluid trap?
- A dab of gel on the breathing tube might spare surgery patients a sore throat — a trial puts it to the test.
- Can a deeper nerve block ease pain after breast surgery?
- Does breast cancer radiation harm a key immune gland? a study investigates
- A web program may ease the emotional toll of chemotherapy hair loss
- Can 3D breast imaging spot more dangerous cancers than standard mammograms?